A Phase Ⅳ Randomized Clinical Trial of Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer
A Phase Ⅳ Randomized Clinical Trial of Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer
This is a phase IV, prospective, single-center, open-label, randomized, controlled study. Eligible patients are randomly assigned into three groups. The investigators propose to evaluate and compare the efficacy and safety of different neoadjuvant chemotherapies in women with primary breast cancer.
Inclusion Criteria:
Female patients, age ≦ 65 years old
Histologically or cytologically confirmed primary breast cancer by core biopsy
Disease stage appropriate for neoadjuvant chemotherapy (T2～T3，N0～2，M0)
No previous treatment for breast cancer
No history of other malignancies
No currently uncontrolled diseased (e.g., ongoing cardiac dysrhythmias, unstable diabetes) or active infection
No history of other malignancies
No currently uncontrolled diseased or active infection
Not pregnant or breast feeding, and on appropriate birth control if of child-bearing potential
Adequate cardiovascular function reserve without a myocardial infarction within the past six month
Adequate hematologic function with:
Adequate hepatic and renal function with:
Knowledge of the investigational nature of the study and Ability to give informed consent
Ability and willingness to comply with study procedures
Exclusion Criteria: